Keyword: Kenneth Frazier

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.

There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to.

There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.

Merck & Co. has a jet engine for growth in its oncology star Keytruda, but long-term it needs more than cancer to keep growth coming.

A judge struck a large portion of a Roundup verdict against Bayer, but as thousands of lawsuits pile up, the litigation is just getting started.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.

There are a lot of intermediate players in today’s pharma supply chain. But expect that to change, Merck CEO Ken Frazier said Wednesday.

A policy change by the board of Merck & Co. will allow Ken Frazier to remain CEO after he turns 65 next year.

A closer look at the Merck's new pricing plan reveals it really isn’t changing all that much, analysts say.